NextCure Entered into a Collaboration and Co-Development Agreement with LegoChem Biosciences to Develop Antibody Drug Conjugates for Cancer
Shots:
- The companies collaborated to develop B7-H4 ADC by using NextCure’s B7-H4 Ab and LCB’s ConjuAll ADC technology for cancer patients
- Additionally, both companies will equally share the costs to develop the molecules and profits on commercialized products & have the option to nominate the two additional targets for ADC development
- NextCure’s FIND-IO platform helps to understand the multiple immune cells to discover and understand targets and structural components of immune cells and their functional impact on a disease to develop immunomedicines. LCB focuses on the R&D of ADCs, antibiotics, anti-fibrotic and anticancer therapeutics
Ref: Globenewswire | Image: NextCure
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
